ClinicalTrials.gg
RecruitingNCT06537596ZOLARUpdated Aug 14, 2026

89Zr-olaratumab Dosimetry in Participants With PDGFR Alpha Positive Solid Tumours and Soft Tissue Sarcoma

A Phase 1 interventional study of 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx) in Soft Tissue Sarcoma and PDGFR Alpha Positive Solid Tumours, sponsored by Telix Pharmaceuticals (Innovations) Pty Ltd. Recruiting at 3 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Telix Pharmaceuticals (Innovations) Pty Ltd (part of Telix Pharmaceuticals Limited) · Phase 1, Interventional, and Diagnostic

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 76 studies in Sarcoma with a site in Australia — 11 open to participants now, 20 under way, none of them phase 3. Sarcoma · Australia.

Planned enrollment
49th of 71
50 · median 111
Started
2024
with 3 others
Phase 1
16 of 76
5 open now
Primary completion
2027-10
later than 11 of 19 live
Registered
71st of 76
by date

Among the 76 studies in Sarcoma with a site in Australia, this one is the 49th largest by planned enrollment of the 71 interventional ones that give a count, is one of 4 that started in 2024, is one of 16 in phase 1, reaches primary completion later than 11 of the 19 other live ones, and was the 71st registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

11 of the 76 studies in Sarcoma with a site in Australia are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 301 Sarcoma studies recruiting now, 191 (63%) set no upper age limit and 83 (28%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Sarcoma with a site in Australia, or all of them as a file.
02

Study summary

Soft Tissue Sarcoma (STS) is a cancer of soft tissues that often expresses Platelet-Derived Growth Factor Receptor (PDGFR)α, a potential therapeutic target. PDGFRα is also found in other advanced solid tumours.

Olaratumab, a PDGFRα-targeted antibody, may be used to deliver radioactive isotopes for imaging or therapy. This first-in-human study will evaluate zirconium-89-labelled olaratumab (⁸⁹Zr-TLX300-CDx) for imaging in patients with STS, selected PDGFRα-positive solid tumours and identification of patients that may benefit from future treatments.

Read the detailed description

Platelet-derived growth factor receptor α (PDGFRα) is expressed in soft tissue sarcoma (STS) and other solid tumours, where it may serve as a therapeutic target. Olaratumab is a PDGFRα-targeted antibody with potential to act as a targeting moiety for both imaging and therapeutic radioisotopes. Its favourable safety profile and ability to bind and be internalised by PDGFRα-expressing tumour cells make it a promising radionuclide targeting agent. ⁸⁹Zr-TLX300-CDx is being developed for PDGFRα PET imaging in STS and selected PDGFRα-positive solid tumours. The aim of this study is to demonstrate tumour targeting of ⁸⁹Zr-TLX300-CDx and assess its safety and radiation dosimetry, to support future development of olaratumab as a radiopharmaceutical.

SCHEDULE OF ASSESSMENTS

Part A

IMAGING:

1 single injection of 89Zr-TLX300-CDx on Day 1 followed by whole-body imaging at 4h ± 0.5h and Day 6 ± 1 post-injection.

OPTIONAL:

Imaging at Day 4 ± 1 post-injection.

Blood Collection for Pharmacokinectics:

Pre-injection, 4h ± 0.5h and 6 days ± 1 day post-injection.

OPTIONAL:

Blood collection at Day 4 ± 1 post-injection.

Part B

IMAGING:

1 single injection of 89Zr-TLX300-CDx on Day 1 followed by whole-body imaging at Day 6 ± 1 post-injection.

OPTIONAL:

Imaging at 4h ± 0.5h post-injection and at Day 4 ± 1 post-injection.

Blood Collection for Pharmacokinectics:

Pre-injection, 4h ± 0.5h and 6 days ± 1 day post-injection.

OPTIONAL:

Blood collection at Day 4 ± 1 post-injection.

Part C:

IMAGING:

1 single injection of 89Zr-TLX300-CDx on Day 1 followed by whole-body imaging at 24h ± 4h, 4 days ± 1 post-injection and 7 days ± 1 day post-injection.

OPTIONAL:

Dynamic imaging 15 min ± 2 min post-injection at selected sites (extended field-of-view scanner available) and static imaging at 4h ± 0.5h post-injection.

Blood Collection for Pharmacokinectics:

Pre-injection, 4h ± 0.5h, 24h ± 4h, 4 days ± 1 day and 7 days ± 1 day post-injection.

03

Conditions studied

  • Soft Tissue Sarcoma
  • PDGFR Alpha Positive Solid Tumours

Browse trials for

Keywords

  • Soft Tissue Sarcoma
  • Solid Tumours
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years of age at the time of signing the .
  2. confirmed diagnosis of soft tissue sarcoma (STS). Patients with indications other than STS, that could be PDGFRα positive, will also be considered This would be subject to case-by-case approval by the Sponsor.
  3. At least one mass of > 2cm in largest diameter seen on standard care imaging (CT or MRI) or at least one lesion detected positive via FDG-PET.
  4. Participants must have consented to provide prior/archival FFPE tumour tissue or /resected tissues collected up to 30 days after visit 2 (89Zr-TLX300-CDx administration) - please refer to the Laboratory manual for description of tissue requirements.

    It is preference that biopsies have been collected within 3 months of trial participation (but not mandatory).

  5. Adequate haematologic function as defined by an (ANC) ≥ 1500/ μL, ≥ 9.0 g/dL, and a count of 100,000/μL obtained.
  6. Adequate hepatic function as defined by a total ≤ 1.5 mg/dL, and (AST) and alanine transaminase (ALT) ≤ 3.0 times the (ULN).
  7. Adequate renal function as defined by serum creatinine ≤ 1.5 × the institutional ULN. If creatinine is above the ULN, the participant's is ≥ 45 mL/min.
  8. (ECOG) performance status of 0 to 2.
  9. Female participants of must have negative pregnancy tests at screening, as well as confirmation of negative pregnancy test result within 24 hours prior to receiving 89Zr-TLX300-CDx. Female participants of childbearing potential or male participants with female partners of childbearing potential must:

    1. be willing to practice full and true sexual abstinence; or
    2. be surgically/permanently sterile or with a history of hysterectomy for women; or
    3. be willing to practice highly effective by using: a non-oral, injected or implanted non-oestrogen progesterone based hormonal method, male condom, vaginal diaphragm, cervical cap, intrauterine device, for 3 months after the administration of 89Zr-TLX300-CDx.

11. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

EXCLUSION CRITERIA:

  1. Known or suspected to olaratumab, DFOsq, 89Zr or any of the .
  2. IgE antibodies against galactose-α-1,3-galactose (α-Gal) above the , >0.7 kU/L.
  3. Exposure to any experimental diagnostic or therapeutic drug within 30 days from the date of planned administration of 89Zr-TLX300-CDx.
  4. Surgery ≤ 2 weeks prior to the administration of 89Zr-TLX300-CDx or significant ongoing complications of surgery. ≤ 2 weeks prior to the administration of 89Zr-TLX300-CDx is allowed.
  5. Exposure to any radiopharmaceutical within 10 half-lives prior to the administration of 89Zr-TLX300-CDx.
  6. Planned to commence systemic antineoplastic therapies, immunotherapy, targeted therapy, radiotherapy and/or surgery for the period between administration of 89Zr-TLX300-CDx and last imaging timepoint, i.e., (Visit 4 for Parts A and B; Visit 5 for Part C). Existing or ongoing therapies may be continued during the imaging window, without .
  7. Serious non-malignant disease (e.g., psychiatric, infectious, or metabolic), unresolved serious symptoms from previous therapies, or any disease that may interfere with the objectives of the study or with the safety or compliance of the participant, as judged by the Investigator.
  8. Pregnant or lactating person.
  9. Participants unable to declare meaningful on their own (e.g., with legal guardian for mental disorders) or unable to tolerate the study procedures.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Part A

    One Injection of 89Zr-TLX300-CDx

    Drug: 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)

  • Experimental
    Part B

    One Injection of 89Zr-TLX300-CDx

    Drug: 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)

  • Experimental
    Part C

    One Injection of 89Zr-TLX300-CDx

    Drug: 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)

Interventions

  • Drug89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)

    Single administration of 89Zr-TLX300-CDx

06

What researchers measure

Primary outcomes

  1. Evaluate clinical safety and tolerability of 89Zr-TLX300-CDx

    Number of Adverse events (AEs)

    Time frame: 30 days

  2. Biodistribution of 89Zr-TLX300-CDx

    Measurement of absorbed radiation doses to organs.

    Time frame: 6 days

  3. Radiation dosimetry of 89Zr-TLX300-CDx

    Measurement of absorbed radiation doses to tumour(s) and whole body.

    Time frame: 6 days

  4. Pharmacokinetics (PK)

    Measure the antibody concentration at each timepoint to determine a PK curve.

    Time frame: 6 days

Secondary outcomes

  1. Determine a suitable antibody mass for administration

    SUV values of tumour lesions and tumour to background organ (e.g. blood/liver/muscle) ratios.

    Time frame: 6 days

Other outcomes

  1. Evaluate the correlation between tumour uptake of 89Zr-TLX300-CDx and PDGFRα expression

    Immunohistochemistry expression of PDGFRα in tumour tissue AND SUV tumour values and tumour to background ratios.

    Time frame: 30 days

  2. Compare the tumour uptake and detection of lesions between 89Zr-TLX300-CDx and standard of care imaging

    89Zr-TLX300-CDx uptake within tumours and organs and Localisation of tumour deposits on conventional imaging (CT, MRI and/or FDGPET)

    Time frame: 30 days

07

Study locations

2 of 3 sites recruiting
  • Princess Alexandra Hospital 199 Ipswich Road, Woolloongabba
    Brisbane, Queensland 4102, Australia
    Recruiting
  • Precision Molecular Imaging & Theranostics Pty Ltd
    Melbourne, Victoria 3051, Australia
    Recruiting
  • GenesisCare Murdoch 100 Murdoch Drive, Murdoch WA
    Perth, Western Australia 6150, Australia
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2027, 36 months after the start.

Of 72 industry-sponsored phase 1 interventional studies under Sarcoma, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 66. This study's planned 36 months is below that.

Counting every sponsor, half of 161 studies reached it within 56 months; a quarter within 35 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2024
First posted
Aug 5, 2024
StartActual
Oct 31, 2024
Primary completionEst.
Oct 2027
CompletionEst.
Dec 2027
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06537596
Responsible party
Sponsor
First posted
Aug 5, 2024
Start date
Oct 31, 2024
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 14, 2026

Study contacts

Brenda Cerqueira, M.Sc
Contact
brenda.cerqueira@telixpharma.com
+61 83180090
Jui Patil
Contact
jui.patil@telixpharma.com
+61 434919406

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion